FiercePharma

Takeda’s stem cell treatment Alofisel flunks phase 3 trial in Crohn's complication

After trimming an early-stage Crohn’s disease candidate from its pipeline this year, Takeda is dealing with the failure of another of its therapies in a related indication. Alofisel (daradstrocel), a ...
Yahoo Finance

Alofisel® (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2

- Data on Patients with Complex Crohn’s Perianal Fistulas Were Presented at the European Crohn’s and Colitis Organisation (ECCO) 2022 Congress 1 - INSPIRE is the First Observational, Multicenter, Post ...
Healio

First patient enrolls in Alofisel registry

Please provide your email address to receive an email when new articles are posted on . Takeda Pharmaceuticals announced that it has enrolled the first patient in its registry established to gather ...
PMLiVE

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Takeda has chalked up a big win this week after receiving a European licence for Alofisel (darvadstrocel), marking the first approved allogeneic stem cell therapy set to hit the EU market. Alofisel – ...
Nasdaq

Takeda Presents Promising Initial Results From INSPIRE Study Of Alofisel

(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK), said on Friday that clinical remission was observed in 65% of patients with Crohn's disease and complex perianal fistulas in a phase III trial, dubbed ...
Financial Post

Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn's Perianal Fistulas

OSAKA, Japan & CAMBRIDGE, Mass. — Takeda (TSE:4502/NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel ® (darvadstrocel) for the treatment of ...
pharmaphorum

Takeda bags Japanese approval for Crohn's cell therapy Alofisel

Takeda has chalked up another milestone for its Alofisel cell therapy for a complication of Crohn's disease, becoming the first allogeneic stem cell therapy to be approved in Japan. Alofisel ...
BioWorld

Takeda’s Alofisel becomes Japan’s first approved allogeneic stem cell therapy with Crohn’s disease nod

Japan’s Ministry of Health, Labour and Welfare approved Takeda Pharmaceutical Co. Ltd.’s Alofisel (darvadstrocel) to treat complex perianal fistulas in patients with non-active or mildly active ...
PharmiWeb

TiGenix and Takeda announce Alofisel®cid:[email protected](darvadstrocel) receives approval to treat complex perianal fistulae in Crohn’s disease in Europe

TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) and Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced that the European Commission (EC) has approved Alofisel ...
PharmiWeb

Takeda Receives Approval to Manufacture and Market Alofisel® (darvadstrocel) in Japan for Treatment of Complex Perianal Fistulas in Patients with Non-active or Mildly Active ...

- Alofisel provides a potential cell-mediated closure option for patients with complex perianal fistulas associated with Crohn’s disease who have shown an inadequate response to at least one existing ...
The Globe and Mail

Alofisel® (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2

“Complex perianal fistulas are a painful, disabling and often embarrassing complication of Crohn’s disease that can be extremely challenging to treat. 9,10,11,12 Despite advances, many patients ...
BioWorld

Takeda’s Alofisel becomes Japan’s first approved allogeneic stem cell therapy with Crohn’s disease nod

Japan’s Ministry of Health, Labour and Welfare approved Takeda Pharmaceutical Co. Ltd.’s Alofisel (darvadstrocel) to treat complex perianal fistulas in patients with non-active or mildly active ...